EUCODIS Bioscience, a company developing proteins for the chemical industry, and Lohmann Animal Health (LAH), a company developing and marketing products for animal nutrition and animal health, today announced the achievement of a major development milestone in their collaboration agreement relating to the optimization of an undisclosed protein.
EUCODIS Bioscience has completed the development of the prototype protein which is intended to be part of an innovative LAH product. This achievement triggered a milestone payment to EUCODIS Bioscience from LAH. The development project has moved into its final phase, with LAH testing the protein in the field.
"The achievement of this milestone underlines the capacity of EUCODIS Bioscience to develop enzymes and other proteins for different industrial applications", said Rudy Pandjaitan, PhD, CEO EUCODIS Bioscience. "Together with the upcoming launch of our first commercial enzyme, this achievement further fuels our efforts to aggressively expand our current European focus into the US and Asian markets."
"We are pleased to work with a development partner such as EUCODIS Bioscience that combines industrial discipline with a versatile and proven technology", said Dr. Bruno Kaesler, Managing Director of LAH. "Using their protein know-how and development expertise improves the R&D efficiency of LAH and helps us to provide superior products to our customers".
2/3 articles remaining | Register to continue reading.